Pharmaceuticals

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

The Senate's new Naloxone Awareness Day highlights a critical shift. As fentanyl rages, a life-saving drug is moving from ambulances to school hallways.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

Silo Pharma has navigated a critical headwind, regaining Nasdaq compliance. This move provides vital stability, allowing the firm to focus on its true test.

Scienture Holdings' Arbli™ just gained 12.5M covered lives. It's not about the $219M market, but the overlooked patients who can't swallow pills.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

A new partnership between Charles River and Lilly TuneLab merges AI with nonclinical testing, aiming to fast-track new medicines and level the field for biotechs.

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.